An increasing number of elderly patients (≥65 years) receive a donor kidney not only from elderly donors after brain death (DBD) but also after circulatory death (DCD). 
INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION
Studies of kidney transplantation in elderly recipients have shown favorable results, demonstrating improved survival compared to waitlisted patients remaining on dialysis. [1] [2] [3] Combined with an expanding geriatric population and a persistent shortage of donor organs, this has led to an upward trend in the acceptance of grafts from older donors fulfilling expanded donor criteria. 4, [5] [6] [7] [8] Between 2011 and 2013, the majority (54%) of deceased donor kidney transplants in the Netherlands were from donations after circulatory death (DCD) 8 , and DCD programs are emerging in many other countries. 9 ,10 DCD kidneys offer a valuable extension of the donor pool, but at the expense of increasing the risk of delayed graft function (DGF) compared with kidneys from donation after brain death (DBD). [11] [12] [13] A recent analysis of the use of DCD donors older than 60 years showed no difference in graft survival between kidneys from DCD or DBD donors. 13 However, the situation in the Netherlands may be different due to specific allocation of organs from older DCD donors to recipients above 65 years within the Eurotransplant Senior
Program (ESP).
By allocating donors aged ≥65 years to recipients aged ≥65 years, the ESP intends to improve the match between life expectancy of donor organs and recipients. The key components are allocation without prospective matching for human leukocyte antigen (HLA) in favor of local allocation, in order to reduce cold ischemia time (CIT) and thus the risk of injury. 14 While all elderly transplant candidates are conventionally listed for regular kidney allocation within both Eurotransplant and the ESP, only non-HLA immunized elderly candidates are additionally eligible for elderly kidney allocation in ESP. Allocation within the ESP is based on urgency points derived solely from waiting time, starting from the first day of maintenance dialysis treatment. A counterbalance system prevents one country in the Eurotransplant region from donating more or fewer grafts to another country, and therefore waiting times differ between countries. 15 The ESP increases availability of elderly donors, thus reducing time on the waiting list. 16 However, the effect of this policy on long-term graft and patient survival in elderly recipients has not been evaluated in a program including DCD kidneys. If elderly DCD kidneys are damaged by the DCD retrieval procedure, this may result in unfavorable outcomes in vulnerable elderly recipients.
We used data from the Dutch Organ Transplantation Registry (NOTR) to analyze patient and graft survival among elderly (≥65 years) recipients of elderly (≥65 years) DBD or DCD kidneys, and compared outcomes to those of elderly recipients of young (<65 years) DBD kidneys, i.e. the optimal deceased donor for elderly recipients. We tested the hypothesis that kidney transplantation in elderly recipients using either young or elderly DBD and DCD kidneys leads to similar transplant outcomes. Furthermore, we compared these results to 1) mortality of elderly waitlisted patients on dialysis, and 2) the outcome of young (<65 years) recipients transplanted with either young (<65 years) DBD or DCD kidneys. Other outcomes were primary non-function (defined as a graft that never functioned in a recipient who lived for at least ten days after transplantation), DGF (defined as the need for dialysis within seven days after transplantation), one-year renal function (expressed as eGFR in ml/min/1.73m 2 , categorized according to the Kidney Disease: Improving Global Outcomes (KDIGO) stages of chronic kidney disease 18 ), and acute rejection (defined as at least one rejection treatment administered within three months after transplantation, excluding primary non-function).
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Data analyses Data analyses Data analyses Data analyses
In accordance with allocation practice in the Netherlands, we defined donors and recipients below the age of 65 years as young and donors and recipients of 65 years and older as elderly. 20 with the rms package (version 4.1-1-1) and the cmprsk package (version 2.2-7).
Kaplan-Meier curves were plotted using GraphPad Prism (version 5.0).
RESULTS
RESULTS RESULTS RESULTS
Baseline differences across age groups Baseline differences across age groups Baseline differences across age groups Baseline differences across age groups Table 1 shows the characteristics of recipients and donors. The median age of young recipients was 48 years, and the median age of elderly recipients was 68 years. DCD donors were more Table 2 shows the observed incidence of transplant outcomes for each patient group.
Corresponding multivariate analyses are shown in Table 3 . In elderly recipients, the primary non-function (PNF) rate was 12.4% for elderly DCD kidneys, 9.8% for young DCD kidneys and 8.0% for young DBD kidneys, with a notably small incidence of 5.7% for elderly DBD kidneys.
Using the elderly recipients of young DBD kidneys as the reference group, adjusted logistic regression indicated no differences in PNF between the subpopulations of elderly transplant recipients. Only 39.7% of elderly recipients of elderly DCD kidneys were alive with a functioning graft five years after transplantation compared to 52.7% of elderly recipients of elderly DBD kidneys.
Among elderly recipients of grafts from young donors, 61.9% with a DCD donor and 61.5% with a DBD donor were alive with a functioning graft at five years. After adjusting for confounders, Cox regression analysis showed that graft failure at five years did not differ significantly between Table 3 . Table 3 . Table 3 . Survival Probability (%)
Elderly recipients of grafts from elderly deceased donors 35 was comparable (61.3%). For elderly recipients of young DBD kidneys, mortality from the start of dialysis to five years post-transplant was virtually identical to that of elderly recipients of young DCD kidneys (49.8% and 49.9%, respectively). If these patients remained on dialysis instead of being transplanted with a non-ESP donor kidney, mortality was higher (63.0%). Table 4 shows eGFR stages at one year after transplantation according to recipient-donor group.
Including patients with graft loss and PNF, 63.8% of elderly recipients of an elderly DCD kidney had eGFR below 30 ml/min/1.73m 2 compared to 45.5% of elderly recipients of an elderly DBD graft (p=0.019). Renal function was significantly better in elderly recipients of either young DBD or young DCD kidneys, with 25.8% and 26.4% having eGFR below 30 ml/min/1. To our knowledge, this is the first study to evaluate outcomes following renal transplantation in elderly patients receiving deceased-donor grafts from either young (<65 years) or elderly (≥ 65 years) donors. In elderly patients, engraftment from elderly DCD donors resulted in an increased mortality risk compared with kidneys from young DBD donors, an effect that was apparent by one year after transplantation. The unadjusted median survival age for elderly recipients was 3.7 years longer when receiving a graft from young DBD donor versus an elderly DCD donor. Our data suggest that elderly recipients of kidneys from elderly donors do not experience a survival benefit compared to remaining waitlisted on dialysis. Renal function was lower in elderly recipients receiving a graft from an elderly donor compared to a young donor, particularly for elderly DCD donors. Strikingly, the incidence of acute rejection in elderly recipients of elderly DBD kidneys was similar to that for young DBD kidneys, but higher in elderly recipients of elderly DCD kidneys.
A number of studies have provided data on graft survival following donation from an older donor, but most exclusively analyzed either DBD 16, [21] [22] [23] [24] [25] [26] [27] [28] [29] or DCD kidneys. 30 Frei and colleagues concluded that allocation of kidneys within the ESP did not negatively affect graft and patient survival when compared with regular allocation of grafts from donors aged ≥60 years to recipients aged 60-64 years. 16 However, their study did not compare ESP-allocated grafts with outcomes in elderly recipients of grafts from donors younger than 65 years, since too few of these recipients were available in their analysis, and no DCD kidneys were included. Summers and colleagues compared several transplant outcomes following engraftment of 1,768 DCD kidneys versus 4,127 DBD kidneys in the UK while investigating the effect of high donor age and increased CIT. 13 They concluded that higher donor age was associated with increased graft loss, and that this was equivalent for DCD and DBD transplants within donor age groups. We also observed an increased risk of death in elderly patients receiving kidneys from elderly DBD or DCD donors compared with younger donors, with a particular increase in risk when the kidney was from an elderly DCD donor. Our study design differs in two important aspects. Firstly, in accordance with ESP allocation, senior donors were defined as aged 65 years or older, as opposed to 60 years or older in the UK study. 13 Next, our data specifically examine the effect of allocation of kidneys from elderly donors to elderly recipients.
The ESP allocation system aims to achieve short ischemia times through local allocation without HLA matching. DBD kidneys allocated via ESP had the shortest CIT.
Interestingly, this was not achieved for DCD grafts, since CIT was not shorter than for kidneys allocated via the regular Eurotransplant program (ETKAS). A reluctance by transplant centers to accept DCD kidneys from elderly donors may play a role in delaying their allocation. Prolonged CIT, and a greater number of HLA mismatches, may contribute to the relatively high primary non-function rate in elderly recipients receiving elderly DCD grafts, and the poorer graft and patient survival with higher risk for DGF and/or acute rejection. 31 It is likely that DCD kidneys from elderly donors are less resilient to ischemia-mediated damage. 32 Strengths of our study are the national cohort of recipients with large numbers in each of the age and donor categories, a high-quality database with good follow up and availability of data on mortality after graft loss. Some limitations should be considered. We were not able to account for center-specific differences in demographics, treatment or outcomes. ESP allocation has clear merits. It has reduced waiting times for elderly recipients and has increased the availability of grafts from younger donors for recipients below 65 years. 16 Eurotransplant outcomes compare favorably with those from the US, as shown in a recent study examining the outcome of DBD kidneys from donors aged ≥65 years. 26 Snoeijs and colleagues concluded that there was no clear advantage for kidney transplantation from a DBD or DCD expanded criteria donor (ECD) compared with continuing dialysis treatment and waiting for transplantation from a standard criteria DBD donor. 33 However, ECD grafts may still provide a survival advantage in elderly recipients if waiting times were substantially shorter than waiting for a standard criteria donor. 1, 34 Elderly recipients of deceased-donor kidneys from a younger donor only waited for 3-4 more months than an ESP donor kidney. This small difference in waiting time is explained by the competitive possibility of an ESP offer for the majority of elderly patients. If elderly patients chose to only be listed for regular allocation, their expected waiting time would be similar to the younger patient group i.e. 12 months longer than that for the elderly recipients of ESP donor kidneys.
Instead of abandoning the allocation of elderly donors and extending waiting times, efforts should be made to increase safe utilization of grafts from elderly donors. Decreasing cold ischemia time, 13 use of machine perfusion 35 and, possibly, histological evaluation of allografts prior to transplantation, 36 might improve the quality and selection of elderly donors, contributing to better outcomes while maintaining the donor pool. Additionally, reintroducing HLA matching when allocating elderly DCD donor kidneys may reduce rejection rates.
In conclusion, our study shows that acceptance of elderly DCD kidneys for elderly recipients is associated with an increased mortality risk. . Left truncated Kaplan-Meier estimates of elderly recipient survival age. The five year patient median survival age was lowest in elderly recipients of elderly DCD kidneys with 70.7 years (CI 68. 4 -73.5) . This was about 8 months higher among elderly with elderly DBD (71.4 years, CI 70.6 -73.4), 2.1 years higher among elderly of young DCD kidneys (72.8 years, CI 71.3 -n.a.), and 3.7 years (74.7, CI 72.1 -80.7) higher for elderly of young DBD kidneys. Results are unadjusted for confounders due to non-proportionality of the hazards over time. Y = young (<65y); d = donor; O=Old (≥65y); r = recipient; DCD = Donation after circulatory death; DBD = Donation after brain death. Corresponding number at risk in boxplots for each category of patients who enter the study when transplanted at certain age. 
